Pharming posts bigger loss than expected; India looks to boost biopharma;

 @FierceBiotech:  Ireland mulls $6B biopharma center. Article | Follow @FierceBiotech

> Biotechnology company Pharming booked a net loss of €28m in the first half of 2010, far above the €8m estimated by analysts and almost double its 2009 first half loss. Report

> India plans to spend around Rs700 crore in the next two years to boost production at biopharmaceutical firms, even as the local industry gears up for a global boom. News

> A startup chemical products company that spun out of Michigan State University laboratories will become the first commercial tenant of Ann Arbor's 174-acre ex-Pfizer campus since the University of Michigan acquired the site in June 2009. Article

> Research organizations, universities, and industry will receive a sum of €6.4 billion next year in the European Commission's largest ever allocation for research and innovation. Article

> Chalk up another addition to the Buffalo Niagara Medical Campus. OncoMed Pharmaceuticals of Great Neck will occupy 4,500 square feet at the Campus' Innovation Center come September, and it will bring new jobs with it. The company provides bio-oncology pharmaceutical care management and pharmacy services. Story

> As Delaware emerges from the biggest recession since the Depression of the 1930s, the state faces serious economic challenges. Efforts to build on existing strengths in medical innovation can help, and a new report from the research firm Battelle and the Council for American Medical Innovation provides a good road map for driving economic growth and improving residents' health across the state. Item

> North Carolina Centeral University has named K. Sean Kimbro director of its Julius L. Chambers Biomedical/Biotechnology Research Institute. Story

And Finally... The most interesting logos in biopharma. Report

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.